Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Canc
The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer. The effectiveness and tolerance of these treatments in current practice will also be evaluated.
| Condition(s) | Biliary Tract Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer. The effectiveness and tolerance of these treatments in current practice will also be evaluated. |
| Who can participate | Inclusion Criteria: * All locations of primitives (intrahepatic CCA, extrahepatic CCA, adenocarcinoma of the gallbladder; ampullomas excluded) * Age \> 18 years * Diagnosed between 2003 and 2030 (minimum follow-up 2 years) * Written written non-opposition +/- signed informed consent for genetic studies (N.B.: exemption requested for a deceased patient) N.B. Authorized inclusion in a therapeutic research protocol Exclusion Criteria: * Patient under guardianship, curatorship or legal protection * Pregnant or breastfeeding women * Any medical, psychological or social situation, which could prevent the compliance with the protocol according to the investigator's assessment * Refusal to participate in the study |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Locations | Amiens, France; Angers, France; Besançon, France; Bobigny, France; Créteil, France; Dijon, France (+26 more sites) |
| Start date | 2022-05-23 |
| NCT ID | NCT04935853 |
| Official listing | https://clinicaltrials.gov/study/NCT04935853 |